Next generation immuno-oncology biomarkers in gastrointestinal cancer: what does the future hold?

References

• Global Cancer Observatory. Colorectal cancer statistics. 2020.
   Google Scholar
• Chen Y, Jia K, Sun Y, et al. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nat Commun. 2022;13(1). doi: 10.1038/S41467-022-32570-Z
   Web of Science ®Google Scholar
• Lei M, Siemers NO, Pandya D, et al. Analyses of PD-L1 and inflammatory gene expression Association with efficacy of Nivolumab ± Ipilimumab in gastric cancer/Gastroesophageal junction cancer. Clin Cancer Res. 2021;27(14):3925–3935. doi: 10.1158/1078-0432.CCR-20-2790
   Web of Science ®Google Scholar
• Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–133. doi: 10.1016/S0140-6736(18)31257-1
   PubMed Web of Science ®Google Scholar
• Ciardiello D, Vitiello PP, Cardone C, et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat Rev. 2019;76:22–32. doi: 10.1016/j.ctrv.2019.04.003
   PubMed Web of Science ®Google Scholar
• Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929–938. doi: 10.1016/j.annonc.2022.05.519
   PubMed Web of Science ®Google Scholar
• Hause RJ, Pritchard CC, Shendure J, et al. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342–1350. doi: 10.1038/nm.4191
   PubMed Web of Science ®Google Scholar
• Kim JH, Seo MK, Lee JA, et al. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers. J Immunother Cancer. 2021;9(12). doi: 10.1136/JITC-2021-003414
   Web of Science ®Google Scholar
• André T, Shiu K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability-high Advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. doi: 10.1056/NEJMoa2017699
   PubMed Web of Science ®Google Scholar
• Battaglin F, Naseem M, Lenz HJ, et al. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol. 2018;16(11):735. doi: 10.1634/theoncologist.2017-0289
   PubMed Web of Science ®Google Scholar
• Villanueva L, Álvarez-Errico D, Esteller M. The contribution of epigenetics to cancer immunotherapy. Trends Immunol. 2020;41(8):676–691. doi: 10.1016/j.it.2020.06.002
   PubMed Web of Science ®Google Scholar
• Kong JH, Ha D, Lee J, et al. Network-based machine learning approach to predict immunotherapy response in cancer patients. Nat Commun. 2022;13(1). doi: 10.1038/S41467-022-31535-6
   Web of Science ®Google Scholar
• Stadler JC, Belloum Y, Deitert B, et al. Current and future clinical applications of ctDNA in immuno-oncology. Cancer Res. 2022;82(3):349–358. doi: 10.1158/0008-5472.CAN-21-1718
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–452. doi: 10.1016/j.immuni.2018.03.014
   PubMed Web of Science ®Google Scholar
• Budimir N, Thomas GD, Dolina JS, et al. Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade. Cancer Immunol Res. 2022;10(2):146–153. doi: 10.1158/2326-6066.CIR-21-0515
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1). doi: 10.1186/S12943-018-0928-4
   Google Scholar
• Sajjadi E, Venetis K, Scatena C, et al. Biomarkers for precision immunotherapy in the metastatic setting: hope or reality? Ecancermedicalscience. 2020;14. doi: 10.3332/ECANCER.2020.1150
   Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi: 10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143(3):330–337. doi: 10.5858/arpa.2018-0043-OA
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. doi: 10.1016/S0140-6736(21)00797-2
   PubMed Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in Advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–462. doi: 10.1056/NEJMoa2111380
   PubMed Web of Science ®Google Scholar
• Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. doi: 10.1016/S0140-6736(21)01234-4
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi: 10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in Advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–4148. doi: 10.1200/JCO.20.01888
   PubMed Web of Science ®Google Scholar
• Yamashita K, Iwatsuki M, Ajani JA, et al. Programmed death ligand‐1 expression in gastrointestinal cancer: clinical significance and future challenges. Ann Gastroenterol Surg. 2020;4(4):369. doi: 10.1002/ags3.12348
   PubMed Web of Science ®Google Scholar
• Grzywa TM, Paskal W, Włodarski PK. Intratumor and intertumor heterogeneity in melanoma. Transl Oncol. 2017;10(6):956. doi: 10.1016/j.tranon.2017.09.007
   PubMed Web of Science ®Google Scholar
• Yan T, Cui H, Zhou Y, et al. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. Nat Commun. 2019;10(1):1–15. doi: 10.1038/s41467-018-07882-8
   PubMedGoogle Scholar
• Yamashita K, Iwatsuki M, Harada K, et al. Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer? Br J Cancer. 2019;121(3):278–280. doi: 10.1038/s41416-019-0515-5
   PubMed Web of Science ®Google Scholar
• Kim HN, Jang J, Heo YJ, et al. PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. Virchows Arch. 2020;476(2):243–250. doi: 10.1007/s00428-019-02653-2
   PubMed Web of Science ®Google Scholar
• Park Y, Koh J, Na HY, et al. PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs. Cancer Res Treat. 2020;52(3):661–670. doi: 10.4143/crt.2019.718
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. doi: 10.1016/S1470-2045(17)30422-9
   PubMed Web of Science ®Google Scholar
• Killock D. Pembrolizumab for HER2+ gastric cancer. Nat Rev Clin Oncol. 2022;19(3):150. doi: 10.1038/s41571-021-00594-x
   PubMed Web of Science ®Google Scholar
• Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:1–9. doi: 10.1155/2014/852748
   Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi: 10.1016/S0140-6736(10)61121-X
   PubMed Web of Science ®Google Scholar
• Taylor C, Hershman D, Shah N, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res. 2007;13(17):5133–5143. doi: 10.1158/1078-0432.CCR-07-0507
   PubMed Web of Science ®Google Scholar
• Mortenson ED, Park S, Jiang Z, et al. Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res. 2013;19(6):1476–1486. doi: 10.1158/1078-0432.CCR-12-2522
   PubMed Web of Science ®Google Scholar
• Park SG, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18(2):160–170. doi: 10.1016/j.ccr.2010.06.014
   PubMed Web of Science ®Google Scholar
• Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells - PubMed. [cited 2023 Jun 21]. Available fom: https://pubmed.ncbi.nlm.nih.gov/11956077/.
   Google Scholar
• Stagg J, Loi S, Divisekera U, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108(17):7142–7147. doi: 10.1073/pnas.1016569108
   PubMed Web of Science ®Google Scholar
• Chaganty BKR, Qiu S, Gest A, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. Cancer Lett. 2018;430:47. doi: 10.1016/j.canlet.2018.05.009
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476–484. doi: 10.1007/s10120-014-0402-y
   PubMed Web of Science ®Google Scholar
• Salem ME, Puccini A, Xiu J, et al. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Oncology. 2018;23(11):1319–1327. doi: 10.1634/theoncologist.2018-0143
   Google Scholar
• Janjigian YY, Maron SB, Chatila WK, et al. First-line pembrolizumab and trastuzumab in HER2-positive esophagogastric cancer. Lancet Oncol. 2020;21(6):821. doi: 10.1016/S1470-2045(20)30169-8
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–730. doi: 10.1038/s41586-021-04161-3
   PubMed Web of Science ®Google Scholar
• Weadick CS, Duffy AG, Kelly RJ. Recent advances in immune-based approaches for the treatment of esophagogastric cancer. Expert Opin Emerg Drugs. 2022;27(1):19–31. doi: 10.1080/14728214.2021.2020757
   PubMed Web of Science ®Google Scholar
• KEYTRUDA® (pembrolizumab) plus trastuzumab and chemotherapy met primary endpoint of progression-free survival as first-line treatment in patients With HER2-Positive advanced gastric or Gastroesophageal Junction (GEJ) adenocarcinoma. 2023.
   Google Scholar
• Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18(1):53–59. doi: 10.1097/PAP.0b013e3182026d72
   PubMed Web of Science ®Google Scholar
• Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797–805. doi: 10.1111/j.1365-2559.2008.03028.x
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. doi: 10.1093/annonc/mdy495
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. doi: 10.1016/S1470-2045(20)30445-9
   PubMed Web of Science ®Google Scholar
• Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–209.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sethi NS, Hinoue T, et al. Comparative molecular analysis of gastrointestinal adenocarcinomas. Cancer Cell. 2018;33(4):721–735.e8. doi: 10.1016/j.ccell.2018.03.010
   PubMed Web of Science ®Google Scholar
• Kim J, Bowlby R, Mungall AJ, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–175.
   PubMed Web of Science ®Google Scholar
• Muzny DM, Bainbridge MN, Chang K, et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–337.
   PubMed Web of Science ®Google Scholar
• Lee KW, Van Cutsem E, Bang YJ, et al. Association of tumor mutational burden with efficacy of pembrolizumab±Chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res. 2022;28(16):3489–3498. doi: 10.1158/1078-0432.CCR-22-0121
   PubMed Web of Science ®Google Scholar
• Wang F, Wei XL, Wang FH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019;30(9):1479–1486. doi: 10.1093/annonc/mdz197
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–206. doi: 10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, et al. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–173. doi: 10.1016/j.ccell.2020.10.001
   PubMed Web of Science ®Google Scholar
• Fancello L, Gandini S, Pelicci PG, et al. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019;7(1). doi: 10.1186/S40425-019-0647-4
   PubMedGoogle Scholar
• Büttner R, Longshore JW, López-Ríos F, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open. 2019;4(1):442. doi: 10.1136/esmoopen-2018-000442
   PubMed Web of Science ®Google Scholar
• Merino DM, McShane LM, Fabrizio D, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the friends of cancer research TMB harmonization project. J Immunother Cancer. 2020;8(1). doi: 10.1136/JITC-2019-000147
   Web of Science ®Google Scholar
• de Castro G, Rizvi NA, Schmid P, et al. NEPTUNE: phase 3 study of first-line durvalumab plus tremelimumab in patients with metastatic NSCLC. J Thorac Oncol. 2023;18(1):106–119. doi: 10.1016/j.jtho.2022.09.223
   PubMed Web of Science ®Google Scholar
• Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441–1448. doi: 10.1038/s41591-018-0134-3
   PubMed Web of Science ®Google Scholar
• Khagi Y, Goodman AM, Daniels GA, et al. Hyper-mutated circulating tumor DNA: correlation with response to checkpoint Inhibitor-based immunotherapy. Clin Cancer Res. 2017;23(19):5729. doi: 10.1158/1078-0432.CCR-17-1439
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Y, Chang L, et al. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer. J Immunother Cancer. 2019;7(1). doi: 10.1186/S40425-019-0581-5
   Google Scholar
• Jin Y, Chen DL, Wang F, et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020;19(1):1–6. doi: 10.1186/s12943-020-01274-7
   PubMed Web of Science ®Google Scholar
• Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–1458. doi: 10.1038/s41591-018-0101-z
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. doi: 10.1158/2159-8290.CD-21-1059
   PubMed Web of Science ®Google Scholar
• Ye Z, Shi Y, Lees-Miller SP, et al. Function and molecular mechanism of the DNA damage response in immunity and cancer immunotherapy. Front Immunol. 2021;12:797880. doi: 10.3389/fimmu.2021.797880
   PubMed Web of Science ®Google Scholar
• Tian H, Gao Z, Li HZ, et al. DNA damage response–a double-edged sword in cancer prevention and cancer therapy. Cancer Lett. 2015;358(1):8–16. doi: 10.1016/j.canlet.2014.12.038
   PubMed Web of Science ®Google Scholar
• Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–3758. doi: 10.1158/1078-0432.CCR-18-4070
   PubMed Web of Science ®Google Scholar
• Hsiehchen D, Hsieh A, Samstein RM, et al. DNA repair gene mutations as predictors of immune checkpoint Inhibitor response beyond tumor mutation burden. Cell Rep Med. 2020;1(3):100034. doi: 10.1016/J.XCRM.2020.100034
   PubMedGoogle Scholar
• Brana I, Massard C, Baird RD, et al. Basket of baskets (BoB): a modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors. 2019;37(15_suppl):TPS3151–TPS3151. doi: 10.1200/JCO20193715_supplTPS3151
   Google Scholar
• Elsayed FA, Kets CM, Ruano D, et al. Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. Eur J Hum Genet. 2015;23(8):1080–1084. doi: 10.1038/ejhg.2014.242
   PubMed Web of Science ®Google Scholar
• Wang F, Zhao Q, Wang YN, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol. 2019;5(10):1504–1506. doi: 10.1001/jamaoncol.2019.2963
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim SY, Baek JY, et al. A phase II study of avelumab monotherapy in patients with mismatch repair-deficient/Microsatellite instability-high or POLE-Mutated metastatic or unresectable colorectal cancer. Cancer Res Treat. 2020;52(4):1135–1144. doi: 10.4143/crt.2020.218
   PubMed Web of Science ®Google Scholar
• Andre T, Berton D, Curigliano G, et al. Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study. 2021;39(3_suppl):9–9. doi: 10.1200/JCO2021393_suppl9
   Google Scholar
• Parikh AR, He Y, Hong TS, et al. Analysis of DNA damage response gene alterations and tumor mutational burden across 17,486 tubular gastrointestinal carcinomas: implications for therapy. Oncology. 2019;24(10):1340–1347. doi: 10.1634/theoncologist.2019-0034
   Google Scholar
• Pilard C, Ancion M, Delvenne P, et al. Cancer immunotherapy: it’s time to better predict patients’ response. Br J Cancer. 2021;125(7):927–938. doi: 10.1038/s41416-021-01413-x
   PubMed Web of Science ®Google Scholar
• Rösler W, Altenbuchinger M, Baeßler B, et al. An overview and a roadmap for artificial intelligence in hematology and oncology. J Cancer Res Clin Oncol. 2023;8:1–10. doi: 10.1007/s00432-023-04667-5
   Google Scholar
• Swaerts K, Dedeurwaerdere F, De Smet D, et al. DeltaMSI: artificial intelligence-based modeling of microsatellite instability scoring on next-generation sequencing data. BMC Bioinf. 2023;24(1):1–14. doi: 10.1186/s12859-023-05186-3
   PubMed Web of Science ®Google Scholar
• Lu Z, Chen H, Jiao X, et al. Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. J Immunother Cancer. 2020;8(2). doi: 10.1136/JITC-2020-000631
   Web of Science ®Google Scholar
• Chowell D, Yoo SK, Valero C, et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol. 2021;40(4):499–506. doi: 10.1038/s41587-021-01070-8
   PubMed Web of Science ®Google Scholar
• Ning J, Sun K, Fan X, et al. Use of machine learning-based integration to develop an immune-related signature for improving prognosis in patients with gastric cancer. Sci Rep. 2023;13(1):1–13. doi: 10.1038/s41598-023-34291-9
   PubMed Web of Science ®Google Scholar
• Tojjari A, Abushukair H, Saeed A. The crosstalk between microbiome and immunotherapeutics: myth or reality. Cancers (Basel). 2022;14(19). doi: 10.3390/CANCERS14194641
   PubMed Web of Science ®Google Scholar
• Peng Z, Cheng S, Kou Y, et al. The gut microbiome is associated with clinical response to anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol Res. 2020;8(10):1251–1261. doi: 10.1158/2326-6066.CIR-19-1014
   PubMed Web of Science ®Google Scholar
• Hibberd AA, Lyra A, Ouwehand AC, et al. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterol. 2017;4(1). doi: 10.1136/BMJGAST-2017-000145
   PubMedGoogle Scholar
• Luu M, Weigand K, Wedi F, et al. Regulation of the effector function of CD8+ T cells by gut microbiota-derived metabolite butyrate. Sci Rep. 2018;8(1):1–10. doi: 10.1038/s41598-018-32860-x
   PubMed Web of Science ®Google Scholar